SLM:NASDAQSLM Corporation Analysis
Data as of 2026-05-26 - not real-time
$22.08
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
SLM trades at $22.08, just above the calculated support of $20.93 and below both the 20‑day SMA ($22.21) and the 200‑day SMA ($25.78), indicating a modestly bearish technical bias. The RSI sits near 50 and the MACD histogram is negative, while volume is on a downtrend and 30‑day volatility is high at roughly 29%, suggesting price swings may continue.
Fundamentally, the stock appears deeply undervalued with a trailing P/E of 6.1 versus an industry average of 16.7 and a dividend yield of 2.35% backed by a low payout ratio. However, the balance sheet is strained: total debt of $6.17 B dwarfs cash of $5.20 B, yielding a debt‑to‑equity ratio of 253% and negative operating cash flow, while recent senior‑note issuances signal active refinancing. The combination of attractive valuation, modest dividend income, and ongoing debt management supports a medium‑term upside target around $29, but high leverage and regulatory exposure to student‑loan policies keep overall risk elevated.
Fundamentally, the stock appears deeply undervalued with a trailing P/E of 6.1 versus an industry average of 16.7 and a dividend yield of 2.35% backed by a low payout ratio. However, the balance sheet is strained: total debt of $6.17 B dwarfs cash of $5.20 B, yielding a debt‑to‑equity ratio of 253% and negative operating cash flow, while recent senior‑note issuances signal active refinancing. The combination of attractive valuation, modest dividend income, and ongoing debt management supports a medium‑term upside target around $29, but high leverage and regulatory exposure to student‑loan policies keep overall risk elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish MACD
- Decreasing volume and high short‑term volatility
- Elevated debt levels limiting upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation discount (P/E 6.1 vs industry 16.7)
- Attractive dividend yield and low payout ratio
- Debt refinancing activity improving balance‑sheet outlook
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Sustained high leverage and potential regulatory changes
- Stable earnings and consistent dividend payments
- Long‑term upside potential toward analyst target of $29
Key Metrics & Analysis
Financial Health
Revenue Growth2.50%
Profit Margin44.93%
P/E Ratio6.1
ROE30.93%
ROA2.57%
Debt/Equity253.08
P/B Ratio2.0
Op. Cash Flow$-328494016
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI50.0
Support$20.93
Resistance$24.02
MA 20$22.21
MA 50$21.77
MA 200$25.78
MACDBearish
VolumeDecreasing
Fear & Greed Index91.05
Valuation
Target Price$29.00
Upside/Downside31.34%
GradeUndervalued
TypeValue
Dividend Yield2.35%
Risk Assessment
Beta1.09
Volatility29.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.